New universal primers for genotyping and resistance detection of low HBV DNA levels

Yongqing Tong, MD, PhD\textsuperscript{ab}, Bei Liu, MM\textsuperscript{c}, Hui Liu, MD\textsuperscript{d}, Hongyun Zheng, PhD\textsuperscript{b}, Jian Gu, MM\textsuperscript{a}, Hang Liu, MD\textsuperscript{b}, Min Lin, BS\textsuperscript{f}, Yali Ding, PhD\textsuperscript{h}, Chunhua Song, MD, PhD\textsuperscript{h, i}, Yan Li, PhD\textsuperscript{h, b}.

1. Introduction

Hepatitis B virus (HBV) is one of the most serious and prevalent health problems affecting >2.4 billion people worldwide.\textsuperscript{[1]} There are >350 million chronic HBV carriers, 75\% of whom reside in the Asia-Pacific region, especially in China. People with hepatitis B are at an increased risk of developing hepatic decompensation, cirrhosis, and hepatocellular carcinoma (HCC). The patients with decompensated cirrhosis have a poor prognosis with a 14\% to 33\% probability of survival for 5 years.\textsuperscript{[12]} The estimated worldwide mortality caused by HBV infection is about 780,000 deaths a year.

Many drugs have been approved for the treatment of chronic hepatitis B. Antiviral therapy is an efficient way to prevent bad clinical outcomes of HBV infection. It has been shown to be effective in suppressing HBV replication, decreasing inflammation and fibrosis in the liver, and preventing progression of liver disease.\textsuperscript{[4]} Currently, there are 2 types of anti-HBV drugs: interferon-alpha (IFN-\textalpha), LAM = lamivudine, LdT = telbivudine, NAs = nucleoside analogs, qPCR = quantitative real-time PCR.

Abbreviations: ETV = entecavir, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, IFN-\textalpha = interferon-alpha, LAM = lamivudine, LdT = telbivudine, NAs = nucleoside analogs, qPCR = quantitative real-time PCR.

Keywords: genotyping, HBV, low DNA, resistance mutation

Abstract

HBV (hepatitis B virus) genotyping is important in determining the clinical manifestation of disease and treatment response, particularly, in patients with low viral loads. Also, sensitive detection of HBV antiviral drug resistance mutations is essential for monitoring therapy response.

As sensitive direct sequencing method for genotyping and the drug resistance mutation detection of low levels of HBV DNA in patients’ plasma is developed by PCR amplification of the DNA with novel universal primers. The novel, common, and universal primers were identified by alignment of RT region of all the HBV DNA sequences in databases. These primers could efficiently amplify the RT region of HBV virus at low DNA levels by directly sequencing the resulting PCR products, and mapping with the reference sequence made it possible to clearly obtain the HBV subtypes and identify the resistance mutations in the samples with HBV DNA level as low as 20 IU/mL. We examined the reliability of the method in clinical samples, and found it could detect the HBV subtypes and drug resistance mutations in 80 clinical HBV samples with low HBV DNA levels ranging from 20 to 200 IU/mL.

This method is a sensitive and reliable direct sequencing method for HBV genotyping and antiviral drug resistance mutation detection, and is helpful for efficiently monitoring the response to therapy in HBV patients.

Editor: Ken Rosenthal.

YT, BL, and HL contributed equally to this work.

This work was financially supported by the Hubei Provincial Natural Science Foundation of China (2010CDB00903), National Natural Science Foundation of China (81070771), National Key Basic Research Program of China-973 Program (2012CB517606), and the National Natural Science Foundation of China (81271689).

All the authors in the manuscript have no conflict of interests to declare.

\* Department of Clinical Laboratory, \# Clinical Molecular Diagnostic Center, Renmin Hospital of Wuhan University, \# Department of Pathology Affiliated Tianyou Hospital of Wuhan University of Science and Technology, Wuhan, \# Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China, \# Pennsylvania State University College of Medicine and Hershey Medical Center, Hershey, PA, \# New York University College of Arts and Science, New York, NY.

Correspondence: Yan Li, Department of Clinical Laboratory, Renmin Hospital of Wuhan University, 99 Ziyang Road of Wuchang District, Wuhan 430060, China (e-mail: yanjili@whmc.edu.cn); Chunhua Song, Pennsylvania State University College of Medicine, Penn State Hershey Children's Hospital, PO Box 850, 500 University Drive, Hershey, PA, 17033 (e-mail: csong@hmc.psu.edu).

Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution-NonCommercial License, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be used commercially.

Medicine (2016) 95(33):e4618

Received: 6 July 2016 / Received in final form: 21 July 2016 / Accepted: 25 July 2016

https://dx.doi.org/10.1097/MD.0000000000004618
(Roche Molecular Systems Inc.). However, the molecular methods for the analysis of the HBV subtype or resistance are currently based on common PCR, the sensitivity of which is only ≥200IU/mL of HBV viral load.[14,15] The detection by common PCR method often fails to detect HBV viral load between 100 and 200IU/mL, and the repeatability of the method is poor. Here, we report a direct sequencing methodology for the analysis of the HBV subtype or resistance detection in a low virus load (from 20 to 200IU/mL).

2. Materials and methods

2.1. Ethics statement

This study was approved by the Institutional Review Board of Renmin Hospital, Wuhan University School of Medicine. A written informed consent was obtained from each participant in accordance with the Ethics Committee of the Renmin Hospital of the Wuhan University.

2.2. Patients and plasma preparations

A total of 90 samples of 3 to 5 mL EDTA-anticoagulated peripheral blood were obtained from individuals for quantitative real-time PCR (qPCR) with COBAS TaqMan HBV Test kit (Roche, Swiss). HBV infection was confirmed in the Department of Infectious Diseases, Renmin Hospital of Wuhan University, and patients were treated with NAs, including lamivudine, adefovir, entecavir, tenofovir, or and famciclovir, for >1 year. The HBV DNA titers for each patient were determined by qPCR as reported previously[16] (data not shown). The HBV DNA titers of 80 of 90 patients were from 20 to 200IU/mL, and 10 of these patients were from 200 to 10^3 IU/mL in the peripheral blood. The patients’ age ranged from 22 to 67 years (median, 42.9 years), and 43 patients had the history of interferon therapy for more than a half year. All samples were centrifuged for 5 minutes at 3000g, and the supernatants were collected and stored at −70°C.

2.3. HBV DNA extraction

DNA was extracted from plasma samples with the UltraSens Virus Kit (QIAamp, German, Cat No: 53706) using the designation buffers and reagents in the kit and following the manufacturer’s manual. Briefly, 0.8 mL Buffer AC and 5.6 µL of carrier RNA solution were pipetted onto the top of 1 mL plasma. After the solutions were mixed and incubated at room temperature for 10 minutes, they were centrifuged to have the supernatant discarded. Next, 300 µL Buffer AR and 20 µL proteinase K were added and vortexed. Buffer AB (300 µL) was added, mixed thoroughly by vortex, and transferred to QIAamp spin column. The solutions were centrifuged once again and the tube containing the filtrate was discarded. The silica pellet was washed with 500 µL Buffer AW1 and 500 µL Buffer AW2, respectively. The nucleic acids were eluted in 30 µL Buffer AVE and stored at −70°C.

2.4. Primers design and PCR analysis

The PCR was designed to amplify the DNA fragment of the full-length sequences of RT (344 aa) (Fig. 1A), wherein the primer sequences were F1, 5'-CTGCTTGGGGTGCTCCAGTT-3'; R1, 5'-GCTAGGAGTCCGAGTATGGG-3' for long sequences of RT (344 aa) (Fig. 1B). The PCR was designed to amplify the DNA fragment of the full-length sequences of RT (344 aa) (Fig. 1A), wherein the primer sequences were F1, 5'-CTGCTTGGGGTGCTCCAGTT-3'; R1, 5'-GCTAGGAGTCCGAGTATGGG-3'; F2, 5'-TTCTTAGGGAATGCTC-3'; and R2, 5'-AAGTACGATATGGG-3', respectively. The F and R primer sequence was: 5'-TTCTTAGGGAATGGGCGTGTT-3', respectively. The primer pair FR reaction was done as follows: 94°C 3 minutes; 94°C 30 seconds, 64°C 30 seconds; 56°C 30 seconds, 72°C 90 seconds, 72°C 10 minutes and the amplification length was about 1230 bp. The PCR amplification with the primer pair FR reaction was done as follows: 94°C 3 minutes; 94°C 30 seconds, 64°C 90 seconds, 72°C 50 seconds, for 35 cycles; 72°C 10 minutes. The PCR amplification with the mixed primer pairs FR and F2R reaction was done as follows: 94°C 3 minutes; 94°C 30 seconds, 64°C 90 seconds, 72°C 50 seconds, 20 cycles; then 94°C 30 seconds, 56°C 30 seconds,
72°C 50 seconds, for 35 cycles; 72°C 10 minutes. The PCR was conducted with HotStar Taq Master Mix Kit (Qiagen, German) according to the recommendations of the manufacturer. The PCR products amplified with primer pairs were electrophoresed on a 1.2% agarose gel for gel purification, and stored at −70°C.

2.5. Sanger sequencing

The purified amplification was sequenced with an ABI PRISM BigDye 3.1 terminator cycle sequencing kit (Applied Biosystems). The upstream sequencing primer was the same as F1, and the downstream primer was the same as R1. The sequencing reaction mixture contained 2 μL of Terminator Ready Reaction Mix, 6 μL of 2.5 Sequencing Buffer, 3 μL of template, 9 μL of deionized water, and 1 μL of either of the 2 PCR primers, primers F1 and R1. The cycle sequencing profile was 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds, and 60°C for 4 minutes, followed by incubation at 4°C. The sequencing fragments were purified with 70% ethanol, 95% ethanol, and 3 mol/L sodium acetate. Sequencing was performed on an ABI Prism 3130 Genetic Analyzer with ABI Prism 3130 Collection and Sequencing Analysis software. The sequences generated by the forward and reverse sequencing primers were assembled and analyzed with the software program Sequencher 5.2.3 (Gene Codes Corporation, Ann Arbor, MI). The resulting complete sequences were translated into amino acid sequences to analyze the HBV DNA mutation.

2.6. HBV genotype analysis

The genotypes were analyzed using the HBV sequences available in the NCBI database (http://www.ncbi.nlm.nih.gov/projects/genotyping), which contains 23 HBV genomic DNA reference sequences for 8 HBV subtypes, including Subtype A (Accession No. X02763, X51970, AF090842), Subtype B (Accession No. D00329, AF100309, AB033554), Subtype C (Accession No. X04615, M12906, AF100311), Subtype D (Accession No. X65259, M32138, X85254), Subtype E (Accession No. X75657, AB032431), Subtype F (Accession No. X69798, AB036910, AF223965), Subtype G (Accession No. AF160501, AB064310, AF405706), and Subtype H (Accession No. AY090454, AY090457, AY090460).
2.7. Phylogenetic analysis

All nucleotide sequences from HBV strains were aligned using the ClustalW 2.0 software with a reference panel of reported 23 HBV genomic DNA sequences available in the HBV sequence database (http://www.ncbi.nlm.nih.gov/projects/genotyping) and full-length RT sequences provided by Stanford University (http://hivdb.stanford.edu/HBV/releaseNotes/), which contains 23 HBV DNA reference sequences for 8 HBV subtypes as above. Pairwise evolutionary distance matrices for the RT nucleotide sequences were computed using the p-distance algorithm of the MEGA software package (version 5.2, 2012; Pennsylvania State University, University Park, PA). Sequence distance matrices were analyzed with conventional statistical software (SYSTAT, v13.0; Systat Software, Inc., Point Richmond, CA) using files derived from Mega distance tables. For RT sequences, a p-distance of 0.12 was found to delineate strains of the same subtype and strains of a different subtype. Phylogenetic analysis was used to identify the HBV subtypes. It could distinguish the subtype for each of the RT region sequence of the Stanford HBV database (Fig. 2A), which is similar to that in NCBI HBV genomic database (Fig. 2B). The data indicated RT region sequence could be used for clinical HBV genotyping. Therefore, we aligned the sequences of the RT region from all the HBV subtypes to design the primers, which could cover almost all HBV subtypes by Vector NT 11.0 software (Invitrogen, Carlsbad, CA). The identified common primers (F1 and R1) were shown in the red frame, which could be used to amplify the RT region of the 23 HBV DNA subtypes from the HBV DNA database (Fig. 2C).

3. Results

3.1. The common primers designed for amplification of almost all HBV subtypes

The RT region of HBV genomic DNA sequences was extracted from NCBI HBV database (http://www.ncbi.nlm.nih.gov/projects/genotyping) and HBV RT region database of Stanford University (http://hivdb.stanford.edu/HBV/releaseNotes/), respectively (Fig. 1). Phylogenetic analysis was used to identify the HBV subtypes. It could distinguish the subtype for each of the RT region sequence of the Stanford HBV database (Fig. 2A), which is similar to that in NCBI HBV genomic database (Fig. 2B). The data indicated RT region sequence could be used for clinical HBV genotyping. Therefore, we aligned the sequences of the RT region from all the HBV subtypes to design the primers, which could cover almost all HBV subtypes by Vector NT 11.0 software (Invitrogen, Carlsbad, CA). The identified common primers (F1 and R1) were shown in the red frame, which could be used to amplify the RT region of the 23 HBV DNA subtypes from the HBV DNA database (Fig. 2C).

We designed the primer F2 and R2, as a universal primer, which could not amplify any HBV DNA sequence, human genomic DNA sequence, or other nucleotide sequence. The F2 and R2 primers are further linked at the end of F1 and R1 to construct another universal primer F and R, respectively (Fig. 1B).

3.2. The specificity of the designed primers

The HBV DNA was extracted from 10 HBV patients’ plasma with HBV DNA levels from $200$ to $10^5$ IU/mL. First, the 2 pairs of primers F1R1 were used to amplify the RT region in the 10 samples. The correct size of the PCR products with F1R1 primers was about 1200 bp length as shown in Figure 3A. The resulting
gelpurified PCR products were sequenced with the primer F1 or R1. The representative sequence is shown in Figure 3B. The resulting sequence was used for the HBV subtyping by blast sequence comparison with the online NCBI HBV database, and the representative data are shown in Figure 3C. We used the pair of FR primers to amplify the RT region, and the correct size of the PCR products for this pair of primer was about 1300bp as shown in Fig. 3D. The PCR products were also sequenced with the primer of F2 or R2 but not F1 or R1 as shown in Figure 3E; and the resulting sequence was blasted online to identify the subtypes as representatively shown in Figure 3F. These data showed that the 2 pairs of primers could efficiently amplify the RT region of HBV. Also, the HBV DNA sequence amplified by the pair of primer F1R1 (Fig. 3B) was consistent with that of primer FR (Fig. 3E), and the resulting HBV subtypes with the 2 pairs of primers (F1R1 and FR) were also identical (Fig. 3C and Fig. 3F).

3.3. Sensitivity of the identified primers for PCR amplification

To examine the sensitivity of the identified primers, HBV DNA was serially diluted from 10^5 to 10^7 IU/mL; and the primer pair was also serially diluted from 10 to 0.1 pmol/L. We tested the sensitivity of the PCR amplification for the pair of primer FR (FR only) and 2 pairs of primers FR plus F2R2 (FR+F2R2), respectively. The result showed that FR could only amplify the HBV DNA > 200IU/mL with the primer of final concentration of 0.5 pmol/L F and 0.5 pmol/L R (Fig. 4A). The FR+F2R2 primers could amplify the HBV DNA at 20IU/mL with each of the primers (F, R, F2, and R2) of the final concentration no <0.5 pmol/L (Fig. 4B). With FR+F2R2 primers, HBV DNA could be detected as low as 20IU/mL, even for the concentration of F or R primer diluted to 0.005 pmol/L with 0.5 pmol/L F2 and 0.5 pmol/L R (Fig. 4C). The PCR products on Fig. 4C were purified and sequenced, and all of the sequences from a to f were identical (Fig. 4D). These data indicated that the designed primers, particularly the mixed primer (FR+F2R2), could efficiently amplify the RT region of HBV DNA with an extremely high sensitivity.

3.4. Reliability of HBV subtyping and resistance mutation detection in clinical samples

The HBV DNA was extracted from 80 patients’ plasma with low load HBV DNA infection. The RT region of HBV was PCR amplified with FR+F2R2 primers at the final concentration of 0.025 pmol/L for F and R and 0.5 pmol/L for F2 and R2. The primers successfully amplified the RT with the correct size in all the samples, and the representative 8 PCR products are shown on Figure 5A. After sequencing the purified PCR products for all the samples with low level of HBV DNA, the accurate subtype for each sample was identified by mapping to NCBI reference sequences through blast sequence comparison with the online HBV database. Figure 5B shows the representative mapped genotypes of B, C, D, and mix B/C. The HBV mutations in the samples were also analyzed by comparing their sequences with NCBI reference sequences. The common resistance mutations such as rtI169, rtV173, rtL180, rtA181, rtT184, rtA194, rtS202, rtM204, rtN236, and rtM250 were found in the samples; also some rare mutations, such as rtL80, rtV84, rtV214 and rtQ215,
we identified in the samples with this method (Fig. 5C). We identified 11.25% (9/80) HBV subtype B, 85.0% (68/80) HBV subtype C, 1.25% (1/80) HBV subtype D, and 2.5% (2/80) HBV subtype mix B/C in the 80 clinical samples (Fig. 6A). The detective mutation frequencies for the most common mutation rtM204 and rtL180 were 35.5% and 29.71%, respectively (Fig. 6B), whereas the rare mutation rtV214 and rtQ215 was 2.90% and 2.17%, respectively (Fig. 6B).

4. Discussion

HBV genotypes are important for the clinical manifestation of disease and treatment response of the patients, particularly those with low HBV loads. Also, sensitive detection of HBV-DNA resistance is essential for monitoring response to therapy. So far there have no common PCR methods available for HBV subtyping or resistance detection for low levels of HBV DNA.

Figure 5. The results of subtypes and drug resistance mutation detections in clinical samples. (A) The bands of polymerase chain reaction products from the patients’ samples with the mixed primer FR and F2R2 by gel electrophoresis. (B) The result of HBV subtypes of the patients obtained by blast sequence comparison of their hepatitis B virus (HBV) sequence with online NCBI HBV database. The HBV subtypes in the patients include B, C, D, and mix B/C subtype. (C) The antiviral drug resistance mutations detected in 80 clinical HBV samples (HBV DNA from 20 to 200 IU/mL).
We developed a sensitive method in this study for efficiently genotyping and detecting resistance mutations in patients with low levels of HBV DNA (20 to 200 IU/mL). Our result showed that this method is a precise and reliable method for clinical application.

This method is characterized by the designed common and universal primers. We identified the common primer F1R1 that could cover all HBV subtypes in the databases. We also designed the universal F2R2 primers, and another universal primers FR by linking F2 and R2 to F1 and R1 primers, respectively. The new designed common primers F1R1 and FR could amplify all 23 HBV subtypes from databases and clinical samples. The F2R2 universal primer could be used as sequence primer for all amplified subtypes in the patients’ samples. This pair of primers was also able to amplify all HBV subtypes if mixed with FR together, which increases the sensitivity of PCR amplification. Therefore, FR+F2R2 have the highest sensitivity for amplification, and we found that they can detect plasma HBV DNA as low as 20 IU/mL.

Antiviral treatment is effective to suppress HBV replication, decreasing the level of serum HBV DNA in the patients. However, drug treatment also induces resistance mutations in the patients. Therefore, sensitive detection of HBV-DNA resistance is essential for monitoring response to therapy. With this method, we could efficiently perform the subtyping and detection of resistance mutations in 90 patient samples including 80 samples with low levels of plasma HBV DNA (from 20 to 200 IU/mL). The ratio of HBV genotypes and resistance mutations is consistent with previous reports. These results indicated this method is a sensitive and reliable direct sequencing method for genotyping and resistance mutation detection in low levels of serum HBV DNA samples.

In summary, we developed a new direct sequencing method for genotyping and detecting resistance mutations in low levels of HBV DNA serum samples with the identified new common and universal primers. This method facilitates early identification of resistance mutation and monitoring therapy response in HBV patients.

References

[1] Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582–92.
[2] Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related compensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442–50.
[3] Jang JW, Chui JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompen-sation in patients with hepatitis B virus-related cirrhosis. Hepatology 2015;61:1809–20.
[4] Yapali S, Talata N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 2014;12:16–26.
[5] Chen EQ, Tang H. The current status of combination therapy of chronic hepatitis B. Eur Rev Med Pharmacol Sci 2013;17:2023–31.
[6] Kim SS, Cheong JY, Cho SW. Current nucleos(t)ide analogue therapy for chronic hepatitis B. Gut Liver 2011;5:278–87.
[7] Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1999;27:1670–7.
[8] Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318–26.
[9] Bozdayi AM, Unalimoglu O, Turkyilmaz AR, et al. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 2003;10:256–65.
[10] Lau GK, Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol 2010;16:315–20.
[11] Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2003;23(Suppl 1):9–19.
[12] Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008;2:147–51.
[13] European Association for the Study of the LiverEASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–85.
[14] Hayashi S, Murakami S, Omagari K, et al. Characterization of novel entecavir resistance mutations. J Hepatol 2015;63:546–53.
[15] Cho WH, Hong SP, Kim BK, et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 2009;14:985–93.
[16] Goedel S, Rulikkoetter M, Wesshaar S, et al. Hepatitis B virus (HBV) genotype determination by the COBAS AmpliPrep/COBAS TaqMan HBV Test, v2.0 in serum and plasma matrices. J Clin Virol 2009;45:232–6.

Figure 6. Frequency of hepatitis B virus (HBV) subtypes and drug resistance mutations in the patients’ samples. (A) The ratio of HBV subtypes in the clinical HBV samples. (B) The ratio of the drug resistance mutations in the clinical HBV samples.